Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Italy / NCT04330651
Recruiting Observational

Post-Surgery Extracorporeal Life Support

NCT04330651 · tracked via the Priya Life Science Italy tracker
Sponsor
University of Florence
Phase
Observational
Started
2004-01
Last updated
2021-04-28

Condition(s) studied

Cardiogenic ShockExtracorporeal Life SupportExtracorporeal Membrane Oxygenation ComplicationPost Cardiac Arrest SyndromePost-cardiac Surgery

Investigational drug(s) / intervention(s)

ECLS

ECLS: Emergency application of Extracorporeal Life Support in post-surgical patients

Study summary

Extracorporeal Life Support (ECLS) may provide pulmonary and circulatory support for patients with acute heart failure refractory to conventional medical therapy. However, indications and effectiveness of ECLS engagement post-surgery remains a concern. The investigators sought to analyze indications, modality and outcomes of PS-ECLS, to identify predictors of early and midterm survival after PS-ECLS. The investigators have recorded prospectively, and analysed data of 209 consecutive PS-ECLS patients between January 2004 and December 2018. Demographic and clinical data before, during and after PS-ECLS were collected and their influence on hospital mortality and outcomes (early and midterm) will analyse. Multivariate analysis of pre PS-ECLS implantation factors (as age, female sex , insulin-dependent diabetes, pulmonary hypertension, STS, type of surgical procedure data, pre-ECLS blood lactate level) will be made for identify prognostic risk factors of in-hospital mortality. Overall survival will be analysed, at 6 months,1-year and 5-years, respectively and the factors influencing mild/term outcome will be investigated.

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: * Patients underwent cardiac surgery Exclusion Criteria: * Age \< 18 years

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Massimo Bonacchi Florence Italy Recruiting

More University of Florence trials in Italy

The Effectiveness of Eptinezumab During a Migraine Attack (the BE-FREE Study) Recruiting
Italian Real-life obServational Study on the effecTiveness, sAfety and Tolerability of Atogepant in Migraine Patients Active, not recruiting
Psychosomatic Intervention in Fibromyalgia. Recruiting
Cross-linked Volume-stable Collagen Matrix Versus Connective Tissue Graft At Implant Site. Active, not recruiting
Gepant treAtments: EffectIveNess and tolERability (GAINER) Recruiting

Other trials for the same condition

Naples Federico II Intensive Cardiac Care Unit Registry (Naples FED2-ICCU Registry) Recruiting
Pharmacological and Mechanical Support Approaches in the Management of Acute Heart Failure in the Regional Network Model for the Management of Cardiogenic Shock Recruiting
Altshock-2 REGISTRY Recruiting
Cangrelor on Top of anticoagUlation in Patients With myocaRdial Infarction-related Cardiogenic Shock/Cardiac Arrest receiVIng VA-ECMO Recruiting
Cardiac Rehabilitation in Patients Acutely Managed for Cardiogenic Shock (ENIGMA) Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04330651 on ClinicalTrials.gov ↗ ← All trials in Italy